tiprankstipranks
Advertisement
Advertisement
Arcutis Stockholders Approve Proposals at 2026 Meeting
PremiumCompany AnnouncementsArcutis Stockholders Approve Proposals at 2026 Meeting
1M ago
Arcutis Earnings Call Signals Momentum Amid Headwinds
Premium
Company Announcements
Arcutis Earnings Call Signals Momentum Amid Headwinds
2M ago
Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
Premium
The Fly
Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
3M ago
Arcutis Biotherapeutics backs FY26 revenue view $480M-$495M, consensus $498.07M
PremiumThe FlyArcutis Biotherapeutics backs FY26 revenue view $480M-$495M, consensus $498.07M
3M ago
Arcutis Biotherapeutics submits Zoryve supplemental new drug application
Premium
The Fly
Arcutis Biotherapeutics submits Zoryve supplemental new drug application
3M ago
Arcutis Biotherapeutics: Near-Term Cost Pressures but Intact Long-Term Growth Thesis Supports Buy Rating
Premium
Ratings
Arcutis Biotherapeutics: Near-Term Cost Pressures but Intact Long-Term Growth Thesis Supports Buy Rating
3M ago
Arcutis announces promotion of Matsuda to EVP, Chief Legal Officer
PremiumThe FlyArcutis announces promotion of Matsuda to EVP, Chief Legal Officer
5M ago
Arcutis (ARQT) Earnings Call Signals Scaled Growth
Premium
Company Announcements
Arcutis (ARQT) Earnings Call Signals Scaled Growth
5M ago
Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131
Premium
The Fly
Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100